Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Liabilities and Shareholders Equity: 2010-2024

Historic Liabilities and Shareholders Equity for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Dec 2024 value amounting to $113.2 million.

  • Lineage Cell Therapeutics' Liabilities and Shareholders Equity fell 7.20% to $89.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $405.4 million, marking a year-over-year decrease of 0.85%. This contributed to the annual value of $113.2 million for FY2024, which is 12.08% up from last year.
  • Latest data reveals that Lineage Cell Therapeutics reported Liabilities and Shareholders Equity of $113.2 million as of FY2024, which was up 12.08% from $101.0 million recorded in FY2023.
  • Lineage Cell Therapeutics' 5-year Liabilities and Shareholders Equity high stood at $174.5 million for FY2021, and its period low was $101.0 million during FY2023.
  • Moreover, its 3-year median value for Liabilities and Shareholders Equity was $113.2 million (2024), whereas its average is $112.6 million.
  • In the last 5 years, Lineage Cell Therapeutics' Liabilities and Shareholders Equity skyrocketed by 61.69% in 2021 and then declined by 29.15% in 2022.
  • Lineage Cell Therapeutics' Liabilities and Shareholders Equity (Yearly) stood at $107.9 million in 2020, then surged by 61.69% to $174.5 million in 2021, then dropped by 29.15% to $123.7 million in 2022, then decreased by 18.31% to $101.0 million in 2023, then increased by 12.08% to $113.2 million in 2024.